Development of multidrug resistance during treatment of isoniazid-resistant tuberculosis [1]

European Respiratory Journal

Volumn 26, Issue 3, 2005, Pages 557-

  Koh, W J ^a   Kwon, O J ^a   Park, Y K ^a   Lew, W J ^a   Bai, G H ^a  

^a Korean Institute of Tuberculosis   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; ORAL ANTIDIABETIC AGENT; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADULT; BACTERIAL GROWTH; BACTERIUM COLONY; CASE REPORT; COUGHING; DIABETES MELLITUS; DRUG SENSITIVITY; DRUG WITHDRAWAL; HUMAN; LETTER; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; HUMANS; ISONIAZID; MALE; MIDDLE AGED; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 24644507059     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00045605     Document Type: Letter

References (5)

1. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
2. Bass JB Jr, Farer LS, Hopewell PC, et al. American Thoracic Society / Centers for Disease Control and Prevention: treatment and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374.
3. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society / Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
4. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1998; 53: 536-548.
5. Nolan CM, Goldberg SV. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Int J Tuberc Lung Dis 2002; 6: 952-958.